The risk of dental bleeding in cardiac patients depends on various factors. Including the type of anticoagulant and antiplatelet drugs and the combined use of these drugs, underlying medical conditions, and the use of other drugs. The medical history of the patient and the details of the drugs (prescription and non-prescription) should be taken into consideration at the beginning of each treatment period and any changes should be checked in each session. Let’s check it differently. Stay with us.
Currently, there is insufficient evidence to directly compare the relative bleeding risk of different anticoagulants and antiplatelets (including newer drugs) for dental patients. According to clinical research conducted by pharmaceutical manufacturers, the incidence of major bleeding events for patients with atrial fibrillation (AF) who take dabigatran, apixaban, and rivaroxaban (Zalerban) is similar to or lower than those who take warfarin. However, it should be noted that this evaluation of the amount of bleeding included spontaneous and operation-related bleeding, not the meaning of dental treatment bleeding.
Patients on combination or dual therapy and taking more than one anticoagulant or antiplatelet drug (or a combination of both) have a higher risk of bleeding than those taking a single drug.
The clinical experience of dental professionals indicates that patients who take two types of antiplatelet drugs (such as Plavix + Aspirin) lead to prolonged bleeding after an invasive procedure. However, once the clot is formed, it is satisfactorily stable and firm. Instead, clinical experience indicates that in patients who take anticoagulants, blood clots form much faster than antiplatelet drugs, but they are easily separated and destroyed.